[Favorable response to corticoid therapy in a patient with transverse myelitis in systemic lupus erythematosus].
Transverse myelitis is one of the most unusual neurologic complications of systemic lupus erythematosus. Its pathogenetic mechanisms are controversial. Several therapeutic regimens have been attempted with contradictory results. Corticotherapy appears to improve prognosis, although some authors question its beneficial effects. The case of a patient with systemic lupus erythematosus and transverse myelitis, who presented a favourable clinical course following early treatment with high-dose corticoids, is reported.
Blanch
J
J
Servicio de Reumatología, Hospitale del Mar, Barcelona.
Pros
A
A
Márquez
M A
MA
Campillo
M A
MA
Martí
N
N
Benito
P
P
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008875:Middle Aged; D009188:Myelitis, Transverse / Q000188:drug therapy* / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D011241:Prednisone
Respuesta favorable a la corticoterapia en una paciente afecta de mielitis transversa en el curso de lupus eritematoso sistémico.